777 49jili

777 49jili MoS for finance Pankaj Chaudhary said that INR 122.29 Cr has been recovered from the erring crypto platforms, including interest and penalty WazirX parent Zanmai Labs owes the government INR 40.51 Cr while CoinDCX and its FIU-registered Indian entity have been booked for evading tax worth INR 26.63 Cr The MoS also informed the Parliament that a total of 47 VDA service providers have registered as reporting entities with the finance ministry’s FIU-IND till date The goods and services tax (GST) authorities have so far booked as many as 17 crypto exchanges for allegedly evading GST to the tune of INR 824.14 Cr. In a written reply to the Lok Sabha, minister of state (MoS) for finance Pankaj Chaudhary said that GST dues (including interest and penalty) worth INR 122.29 Cr, have, however, been recovered from the crypto platforms. Of the total INR 824 Cr tax evasion, crypto giant Binance’s subsidiary, Nest Services, alone accounts for 87%, or INR 722.43 Cr , while WazirX parent Zanmai Labs owes the government INR 40.51 Cr. CoinDCX and its FIU-registered Indian entity, Neblio Technologies, have been booked for evading tax worth INR 26.63 Cr. On similar lines, CoinSwitch Kuber is under the scanner for GST evasion to the tune of INR 14.13 Cr and ZebPay is under the radar for evading GST worth INR 7 Cr. Other crypto exchanges that have been booked by authorities include BuyUcoin, UnoCoin, Flipvolt Technologies, among others. In his reply, the MoS also said that four “investors”, dealing in virtual assets, have so far been probed for evading GST worth INR 1.76 Cr. However, INR 2.4 Cr has been recovered from these “investors”. Chaudhary also informed the Parliament that a total of 47 virtual digital asset (VDA) service providers have registered as reporting entities with the finance ministry’s Financial Intelligence Unit (FIU-IND) till date. FIU oversees trade in VDAs and ensures crypto exchanges comply with the Prevention of Money Laundering Act (PMLA) and the VDA taxation framework. All crypto platforms have to mandatorily register as reporting entities to offer crypto trading services in India. The GST liabilities are expected to further increase regulatory burden and costs for the crypto platforms as they look to cash in on the ongoing crypto boom . Step up your startup journey with BHASKAR! From resources to networking, BHASKAR connects Indian innovators with everything they need to succeed. Join today to access a platform built for innovation, growth, and community.

Stock market today: S&P 500, Nasdaq close at record highs as tech surges to kick off December

Cyber Monday Xbox Series S deals: Get the console at up to 25% offS. Dakota St. 75, Missouri St. 55Qatar University celebrates graduates of 2023-2024 Honours Programme

Biden's broken promise on pardoning his son Hunter is raising new questions about his legacy WASHINGTON (AP) — President Joe Biden’s decision to go back on his word and pardon his son Hunter wasn't all that surprising to those who are familiar with the president's devotion to his family. But by choosing to put his family first, the 82-year-old president has raised new questions about his legacy. Biden has held himself up as placing his respect for the American judicial system and rule of law over his own personal concerns. It was part of an effort to draw a deliberate contrast with Republican Donald Trump. Now, both his broken promise and his act of clemency are a political lightning rod. Some Democrats are frustrated over Joe Biden reversing course and pardoning his son Hunter ATLANTA (AP) — Already reeling from their November defeat at the polls, Democrats now are grappling with President Joe Biden's pardoning of his son for a federal felony conviction — after the party spent years slamming Donald Trump as a threat to democracy who operates above the law. The White House on Monday struggled to defend the pardon, claiming the prosecution was politically motivated — a page out of Trump's playbook. That explanation did not satisfy some Democrats who are angry that Biden’s reversal could make it harder to take on Trump. Hezbollah fires into Israel-held area after multiple Israeli strikes in Lebanon since truce began JERUSALEM (AP) — Hezbollah fired into a disputed border zone held by Israel after multiple Israeli strikes inside Lebanon since a ceasefire took hold last week. The militant group said the volley, its first during the truce, was a warning shot in response to what it called repeated Israeli violations. Israeli leaders threatened to retaliate, further straining the fragile U.S.- and French-brokered ceasefire. Israeli strikes in recent days, including a string of hits on Monday, have killed at least four people in Lebanon. U.S. officials said the ceasefire was largely holding. Key players in Syria's long-running civil war, reignited by a shock rebel offensive BEIRUT (AP) — Syria’s civil war has exploded back onto the world stage after insurgents poured out of their main bastion in northwestern Syria and seized large parts of nearby Aleppo, Syria’s largest city, and dozens of nearby towns and villages.. The insurgents offensive triggered the heaviest clashes in the country since a March 2020 cease-fire brokered by Turkey and Russia, who back rival sides in the conflict. Five countries have military presence in Syria including the U.S. that has troops deployed in the country’s east, Turkey that controls parts of northern Syria, Israel that has presence in the Golan Heights and Russia and Iran that have been a main backer of Syrian President Bashar Assad. Woman driving drunk who killed bride still in her wedding dress sentenced to 25 years in prison A woman who admitted to drinking and who was driving well over twice the speed limit when she smashed into a golf cart killing a bride who had just got married at a South Carolina beach has been sentenced to 25 years in prison. Jamie Lee Komoroski pleaded guilty Monday to reckless homicide and three felony driving under the influence charges. Police said the 27-year-old drank at several bars on April 28, 2023, and was driving 65 mph on a narrow Folly Beach road when she slammed into a golf cart leaving a wedding. The bride, 34-year-old Samantha Miller, died still wearing her wedding dress. Florida woman sentenced to life for zipping boyfriend into suitcase, suffocating him A 47-year-oldFlorida woman has been sentenced to life in prison for zipping her boyfriend into a suitcase and leaving him to die of suffocation amid a history of domestic and alcohol abuse. Circuit Judge Michael Kraynick imposed the sentence Monday in Orlando on Sarah Boone for the 2020 killing of 42-year-old Jorge Torres. A jury deliberated only 90 minutes Oct. 25 before convicting Boone of the second-degree murder of Jorge Torres after a 10-day trial. Boone had insisted she was herself a victim of domestic violence at the hands of Torres and had pleaded not guilty. Already buried under snow, Great Lakes region expected to see more stormy weather this week Some storm-weary residents of the Great Lakes region have seen continued snowfall and are facing the prospect of even more accumulations this week. Lake-effect snow continues to fall on parts of western New York that were already blanketed with a foot or more over the past four days. Lake-effect snow warnings are in effect through Tuesday night in parts of Ohio, New York and Pennsylvania. Snow fell in western Michigan overnight, and heavier, persistent snow of up to a foot was expected to follow into Monday. Meanwhile, Alaska's capital got more than a foot of snow over the weekend. The National Weather Service says the wintry weather is stronger than Juneau usually sees this time of year. Stock market today: Rising tech stocks pull Wall Street to another record NEW YORK (AP) — Technology stocks pulled Wall Street to another record amid mixed trading. The S&P 500 rose 0.2% Monday after closing November at an all-time high. The Dow Jones Industrial Average fell 0.3%, and the Nasdaq composite gained 1%. Super Micro Computer, a stock that’s been on an AI-driven roller coaster, soared after saying an investigation found no evidence of misconduct by its management or the company’s board. Retailers were mixed coming off Black Friday and heading into what’s expected to be the best Cyber Monday on record. Treasury yields held relatively steady in the bond market. Cyber Monday shoppers expected to set a record on the year's biggest day for online shopping Consumers in the U.S. are scouring the internet for online deals as they look to make the most of the post-Thanksgiving shopping marathon on Cyber Monday. The National Retail Federation coined the term for the Monday after Black Friday in 2005. Even though e-commerce is now part and parcel of many people’s regular routine, Cyber Monday continues to be the biggest online shopping day of the year, thanks to steady discounts and a fair amount of hype. Several major retails actually started their Cyber Monday promotions over the weekend. Consumer spending for the online shopping days between Thanksgiving and Cyber Monday provides an indication of how much shoppers are willing to spend for the holidays.Donald Trump Jr. sparked an social media exchange involving Joe Rogan and Elon Musk as the trio discussed the latter potentially buying MSNBC. UFC commentator and podcast host Rogan even queried whether he could take over from Rachael Maddow as an anchor on the network if the world's richest man was to stage a shock takeover . The firm has been embroiled in turmoil recently, with staffers described as in "a panic" after it was revealed that NBC parent Comcast may spin off the channel. It was reported by the New York Post that MSNBC mainstays including Maddow, Chris Jansing and Katy Tur were involved in a meeting at MSNBC headquarters at 30 Rock this week as they discussed plans. Sources informed the publication that a change in "name, logos and headquarters" could be in the offing, with confusion over ensuing over how plans may be brought to fruition. Now, Trump Jr. has prompted tech billionaire Musk to consider bidding to buy the entity during a conversation between the pair on X after it was claimed that MSNBC could be up for sale. Jon Jones clarifies retirement plan at UFC 309 with Tom Aspinall watching on Jon Jones paid tribute to Donald Trump after UFC 309 win in front of President-elect After reading the speculation that Comcast will put MSNBC up for sale, Trump Jr. fired a message the way of Musk , saying: "Hey @elonmusk I have the funniest idea ever!!!", prompting the Tesla tycoon to reply "How much does it cost?" before the son of the U.S president elect added: "I mean it can’t be much. Look at the ratings." Following on from this, Musk flirted with the idea of a bid for the firm in a separate post, saying: "The most entertaining outcome, especially if ironic, is most likely," to which UFC commentator Rogan then replied: "If you buy MSNBC, I would like Rachael Maddow’s job. I will wear the same outfit and glasses, and I will tell the same lies," as the billionaire remarked: "Deal." Following on from this, Trump Jr. piped up once more as he said of Musk and Rogan's remarks: "This is getting really interesting. It has to happen," before adding: "Ok @elonmusk & @joerogan. Since this is getting interesting I’ll throw my hat in the ring as well. I’ll mimic Lawrence O’Donnell... minus the castration of course. That’s a bridge too far." These comments come in the wake of the ratings downturn that the trio were referring to in the wake of the result of this month's U.S presidential election. According to The Daily Beast , MSNBC has purportedly seen a drop in ratings of 40 percent based on last year's figures. Putting the decrease in viewership down to the political climate, an insider told that report: "We were so Harris propaganda that when she lost, viewers were shocked. It turned into one giant circle j--- and echo chamber. If MSNBC wants to be of service to its viewers, they can’t keep them in fantasy land." Follow us on X for the best and latest in sports news DON'T MISS Joe Rogan issues three-word response to Mike Tyson vs Jake Paul to sum up sad fight Stipe Miocic told Joe Rogan why he still worked as firefighter while UFC champion Joe Rogan reels off Kamala Harris' banned subjects for podcast appearance Following this drop in ratings, anchor Maddow has signed a new deal with the MSNBC network, taking a paycut from her usual $30 million to a lesser $25 million pay-packet, as per The Ankler . Meanwhile, a source told the report: "This is a difficult time and they needed to keep her. No one else can do what she does. You can’t build a brand like it overnight.2 In addition, the unrest within the broadcast media landscape was also shown as Chris Wallace announced his intentions to leave CNN. The veteran figure said of the call: "It doesn’t matter what was or wasn’t said in that meeting because I had already decided with my wife six months ago to leave CNN. Any further speculation is irrelevant."A pair of teams with minimal rest will face off in Nassau, Bahamas, on Sunday when No. 22 St. John takes on Georgia. St. John's (5-1), which will play its third game in four days, began the stretch in the Bahamas Championship on Thursday, dropping a heartbreaker to No. 13 Baylor. The Red Storm led by 18 in the first half before Baylor forced overtime. From there, St. John's rallied from five down with 1:47 left to send the game to a second overtime, where it saw Baylor knock down a pair of 3-pointers in the final seven seconds -- including Jeremy Roach's buzzer-beater -- to knock off the Red Storm 99-98. In the third-place game on Friday, St. John's breezed past Virginia 80-55. RJ Luis Jr. led the way with 18 points and four steals, followed by Kadary Richmond's 12 points, as the Red Storm took a one-point lead with 15:21 left in the first half and didn't trail again. "I'm really impressed with our guys, coming off a double-overtime, extremely emotional loss," St. John's head coach Rick Pitino said. "To respond that way was extremely impressive, both offensively and defensively." Pitino, in his second year with the Red Storm, was moved by something off the court on Friday, involving captain Zuby Ejiofor, who chipped in eight points, nine boards, two steals and two blocks. Ejiofor was serenaded by St. John's fans during the win, following his two missed free throws at the end of double overtime against Baylor. "When you've only been in a job for a year, you search for things you love about a place," Pitino said. "Tonight I found out what I love about St. John's. Our fans chanted Zuby's name the whole game, which doesn't happen anywhere else in America. I was really impressed with our fans and I thank them for making Zuby feel good, because he gives you all the energy." Luis leads the Red Storm with 17.3 points per game, followed by Ejiofor (10.7), Aaron Scott (10.5), Deivon Smith (10.3) and Richmond (10.2). Georgia enters Sunday's matchup looking to rebound from its first loss after falling to No. 15 Marquette 80-69 on Saturday. Georgia (5-1) battled back from a 15-point, second-half deficit, but was held to just three points over the final 4:57 in Saturday's loss. Blue Cain led the Bulldogs with a season-high 17 points, including five 3-pointers. "It's a process. It's a journey with this team," Bulldogs head coach Mike White said. "It's about continuing to make strides, continuing to protect our culture. ... At the end of the day, wins and losses are going to take care of themselves. We just have to embrace the process and enjoy it." Five-star freshman recruit Asa Newell was held to a season-low nine points but leads the team with 15.5 points per game. Silas Demary Jr. is second with 13.8. --Field Level Media

NoneMontreal anti-NATO protest ends in three arrests, several injuries - The Globe and MailNikki Haley skewers controversial Trump nominees

KYAN Technologies’ cancer response prediction platform shows high accuracy for leukemia in clinical study publication

Meet three incoming EU lawmakers in charge of key tech policy areasOttawa police arrest suspect in Mooney's Bay area shootingmade history a year ago this month when the FDA approved Casgevy (exagamglogene autotemcel), the CRISPR-edited therapy it co-developed with , to treat sickle cell disease (SCD). A month later, the agency authorized Casgevy to treat transfusion-dependent beta thalassemia in patients 12 years and older. Yet CRISPR Therapeutics’ stock has failed to sustain the momentum it built when it reached its 52-week high of $91.10 on February 22, a day after the company reported positive fourth-quarter and full-year 2023 results. Since then, Casgevy’s patient uptake has progressed slower than analysts expected. While some have cited Casgevy’s list price of $2.2 million per course of treatment as a cost that insurers have balked at bearing, Kevin Niehoff, associate director at IPD Analytics told Managed Healthcare Executive (MHE) he believed price was less a barrier than the fact that SCD patients have many other treatment alternatives, such as stem cell or bone marrow transplants, as well as hydroxyurea. From a 52-week high of $91.10 on February 22, CRISPR Therapeutics shares have to $49.51 as of Thursday, though they Friday to $51.56 in afternoon trading as of 2 p.m. ET. Over the past month, two electronic transfer funds (ETFs) of ARK Investment Management (ARK Invest)—the high-profile firm led by chief investment officer and portfolio manager Catherine D. (Cathie) Wood—have largely been swimming against the investor tide by snapping up more than 1 million shares of CRISPR Therapeutics shares, mostly raising its stake in the company in recent weeks. From a reported market value of $352,285,403 at the end of the third quarter, ARK’s holdings in CRISPR Therapeutics climbed 16% to $409,634,402.21 as of Friday, based on its holdings of 8,273,771 shares. Most of ARK’s stake in CRISPR Therapeutics consists of the 6,453,394 shares held by Ark Invest’s , with a market value of $319,507,536.94—the seventh highest market value among the 33 companies in which ARKG holds shares—and a portfolio weight of 4.56% The remaining 1,820,377 shares valued at $90,126,865.27 are held by the firm’s . CRISPR Therapeutics holds the second largest market value among ARKG’s 37 portfolio companies—and a portfolio weight of 7.68%. Without citing CRISPR Therapeutics by name, Wood offered a likely explanation on a recent podcast for why the ARK ETFs have been bullish on the company in recent weeks. “Many healthcare analysts think that curing a disease is not going to be good business, even though it’s amazing for humanity. They think that a cure is one and done, which it is with gene editing,” Wood observed on the November 25 episode of “The Important Part: Investing with Liz Thomas.” “The old model is almost like an annuity, a regular payment monthly for that prescription, out for however long the patent lasts. We believe a cure in business terms is going to be worth two to—depending on the indication—20 times more valuable than a traditional medication,” Wood projected. “So, stay tuned for our research. We’re putting out a lot in that area because we believe it is so misunderstood.” A closer look between Wednesday and Friday, however, shows that the ARK funds followed dips in CRISPR Therapeutics’ share price late last week with selloffs of shares in the company. On Thursday, when CRSP shares from $51.24 to $51.14, ARK trimmed its holdings by 5,864 shares (down 0.1% from Wednesday), reducing its total market value by 0.3% or $1,135,639.78. But by Friday, when the stock to $49.51, ARKK and ARKG shrunk their combined holdings by 78,936 shares (down nearly 1% from Thursday), a market value decline of 4% or $17,523,136.05. So as with other investors, the ARK funds appear to have moved beyond the positive commercial momentum for Casgevy shown in third-quarter results released last month by CRISPR Therapeutics and Vertex. Vertex leads global development, manufacturing, regulatory and commercialization of Casgevy, with support from CRISPR Therapeutics. According to Vertex: • As of mid-October, 45 of the planned 75 authorized treatment centers (ATCs) have been activated in all regions of the world where Casgevy has been approved—the U.S., the European Union, Great Britain, Saudi Arabia, Bahrain, Canada, and Switzerland. • Cell collection had begun in about 40 patients, double the approximately 20 reported after the second quarter, while additional patients have received infusions. • The first $2 million in revenue has been generated from the first commercial patient dosed with Casgevy during Q3. That revenue was included within the $2.772 billion in product revenue that Vertex reported for the quarter. “We view the Casgevy progress as a (+)ve [positive] indicator of getting pts [patients] in the funnel, and expect a majority of ~40 pts will get tx’d [treated] w/in 1–2 quarters,” Maury Raycroft, PhD, equity analyst with Jefferies, projected in a November 5 research note. “It can take ~5–6mos from cell collection to tx. Pt demand is high, and VRTX is adding a 3rd manuf[acturing] facility w/ Lonza.” Raycroft added that Casgevy’s opportunity to attract patients in the Middle East region was “underappreciated and appealing,” with about 23,000 patients eligible. Following a meeting between CRISPR Therapeutics executives and Jefferies analysts at the firm’s London Healthcare Conference late last month, Raycroft reported that management “is pleased w/ how the ‘funnel’ trajectory is playing out commercially as underlying demand/interest has been very strong WW [worldwide] along w/ payer support. It’s only a mechanics question now as more centers get activated.” Writing in a November 20 research note, Raycroft and four Jefferies colleagues reported CRISPR Therapeutics executives expect momentum to build up in coming months, referring to the slow but steady and gradually progressing launch of Yescarta (axicabtagene ciloleucel), the chimeric antigen receptor T-cell (CAR-T) cancer treatment marketed by the Kite subsidiary of following FDA approval in 2017. CRISPR Therapeutics executives told Jefferies analysts the market potential for Casgevy stems from the presence of some 25,000 severe SCD patients in the U.S., another roughly 30,000 in the Middle East, and unspecified growing numbers in the U.K. & France than originally envisioned. In its third-quarter investor presentation, CRISPR Therapeutics pinpointed about 23,000 patients in Saudi Arabia and Bahrain alone, plus about 35,000 patients in the U.S. and Europe combined. “Mgmt [management] noted two areas, where they continue to invest are on global extension and capacity expansion, anticipating the demand,” Raycroft wrote adding that 2024 Casgevy-related expenses have been trending around ~$0.5 billion. Vertex shoulders 60% of costs and enjoys that percentage of profits, with the remaining 40% of costs and profits going to CRISPR Therapeutics. Also positive on Vertex’s commercial progress with Casgevy has been analyst Sami Corwin, PhD, and two colleagues at William Blair. “We view the treatment of the first commercial Casgevy patient as a milestone for the companies and believe they have established the infrastructure to support significant revenue generation in 2025 as more cell collections are converted into cell infusions,” Corwin and colleagues wrote November 5 in a research note. • shares from 74 cents to 49 cents in after-hours trading Wednesday after the company said it will carry out a 1-for-20 reverse stock split following approval by both its board and stockholders at a reconvened annual meeting held that day. Bluebird acknowledged that its primary goal is to increase the per share market price of its common stock to regain compliance with NASDAQ’s minimum bid price requirement for continued listing. The reverse stock split is expected to become effective at 5 p.m. ET on December 12, and the first reverse-split shares will start trading the following day. The drop partially wiped out a 105% gain earlier that day, from 36 cents to 74 cents, after the company announced that it reached agreement with the Center for Medicare and Medicaid Innovation(also called the CMS Innovation Center) to offer an outcomes-based agreement for the gene therapy LyfgeniaTM (lovotibeglogene autotemcel) under the Cell and Gene Therapy Access Model. • shares from $20.04 to $29.85 on December 2, after the company joined Zai Lab (NASDAQ: ZLAB; HKEX: 9688) to announce positive topline results from the pivotal Phase III PANOVA-3 trial (NCT03377491) assessing its Tumor Treating Fields (TTFields) therapy as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. TTFields met the study’s primary endpoint by showing a statistically significant improvement in median overall survival (mOS) versus gemcitabine and nab-paclitaxel alone, Novocure said. In the intent-to-treat population, patients treated with TTFields plus gemcitabine and nab-paclitaxel had an mOS of 16.20 months vs. 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone. • shares from $3.36 to $8.40 on December 2 after the company reported positive final results from the randomized Phase II trial (NCT04731467) evaluating its lead oncology drug CM24 in patients with pancreatic ductal adenocarcinoma (PDAC). Those results showed a consistent and continuous decrease of the PDAC biomarker CA19-9 in the experimental arm reaching a median percentage reduction from baseline of approximately 80%, vs. a 40% increase in the control arm. The trial assessed CM24—a humanized monoclonal antibody designed to block CEACAM1—in combination with Bristol Myers Squibb’s immune checkpoint inhibitor Opdivo (nivolumab) plus standard-of-care (SoC) chemotherapy in second-line metastatic PDAC patients vs. SoC chemotherapy alone. • shares over two days after the company said it will evaluate potential next steps for REL-1017 after acknowledging that the NMDA inhibitor was unlikely to meet with statistical significance the primary efficacy endpoint of the Phase III Reliance II trial (NCT06011577), which is assessing the drug for use in combination with other approved anti-depressants for major depressive disorder (MDD). The trial’s Independent Data Monitoring Committee (DMC) concluded during a pre-planned interim analysis that continuing Reliance II would be futile. Shares from $2.77 to 63 cents Wednesday, then Thursday to 45 cents after Mizuho Securities analyst Uy Ear downgraded the stock from “Outperform” to “Neutral” and slashed the firm’s 12-month price target 96% from $23 to $1. • shares from 95 cents to 51 cents Tuesday after the company said it entered into a definitive agreement to immediately exercise warrants to purchase up to 4,064,040 shares of common stock issued by the company on August 22, at $1 per share. The sale is designed to generate more than $4 million in gross proceeds—about double the company’s $2.168 million market capitalization. A day earlier, Revelation shares rose 25% after the FDA accepted the company’s investigational new drug (IND) application for Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ). The decision allowed Revelation to launch a U.S.-based Phase Ib trial assessing Gemini as a preconditioning treatment in patients with chronic kidney disease. Revelation shares have cratered 98% over the past year, from $22.95 on December 4, 2023.

Putin Threatens To Bomb UK After Ukraine Uses British Long-Range Missiles To Attack RussiaNoneNone